Treatment with bemdaneprocel (BRT-DA01), BlueRock Therapeutics’s investigational cell-based therapy, was safe and well tolerated among patients with advanced-stage Parkinson’s disease, according to top-line results from a Phase 1 clinical trial. Furthermore, data also showed that transplantation was feasible, and there was evidence of cell survival and engraftment in…
The Parkinson’s Foundation has expanded its Global Care Network by adding four Centers of Excellence and four Comprehensive Care Centers to increase access to specialized multidisciplinary care for people with Parkinson’s disease. This expansion recognizes centers within a broad geographic region, including the first-ever designations in Wisconsin,…
Researchers have uncovered new evidence that activity in the gut can directly influence brain function, a relationship that’s been proposed to contribute to Parkinson’s disease. Using specialized fibers with the ability to stimulate nerve cells with light, called optogenetics, the scientists found that by altering cell activity in the…
Freeline Therapeutics announced plans to leverage knowledge gained from its FLT201 gene therapy program in Gaucher disease to advance a similar candidate to treat people whose Parkinson’s is tied to mutations in the GBA1 gene. “Our GBA1-linked Parkinson’s disease program is a natural extension of our…
Certain biomarkers in the blood may help doctors in determining whether a person has Parkinson’s disease or atypical parkinsonism, both of which show similar symptoms, a study reported. Three biomarkers — neurofilament light chain (NfL) and malondialdehyde (MDA), particularly, but also 24S-hydroxycholesterol (24S-HC) — were found at significantly…
Carl McLain, a grandfather and Parkinson’s disease patient, reports enjoying a much-improved quality of life since undergoing deep brain stimulation (DBS), a surgical treatment generally advised for those failing to respond to other disease therapies. McLain 77, said he began experiencing mysterious leg pain, anxiety, depression, and…
BrainTale raised €4.5 million (about $5 million) to speed further development of software that can decode changes in the brain’s white matter into information that can predict, diagnose, and monitor the progression of diseases such as Parkinson’s. With this round of financing, led by investors Capital Grand…
Coya Therapeutics has secured an exclusive license to patent rights and know-how related to the company’s experimental anti-inflammatory therapy COYA 301, alone or in combination with other molecules, for Parkinson’s disease. The license was part of an agreement with UNeMed, the technology transfer office of the University…
UB-312, an experimental vaccine by Vaxxinity, appeared safe and well tolerated and was able to produce an immune response against toxic alpha-synuclein protein aggregates in people with early Parkinson’s disease, according to data from a clinical trial. According to the company, UB-312 met the primary objectives of the…
Following a positive safety review, Annovis Bio‘s Phase 3 clinical trial testing oral buntanetap for the treatment of early-stage Parkinson’s disease can move forward as originally designed, the company announced. That positive review came from the Data and Safety Monitoring Board (DSMB), an independent group of experts, which…
Get regular updates to your inbox.
